Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma Journal Article


Authors: Krishnan, A.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X.; Qi, K.; Londhe, A.; Pei, L.; Ammann, E.; Kobos, R.; Smit, J.; Parekh, T.; Marshall, A.; Slavcev, M.; Usmani, S. Z.
Article Title: Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Abstract: Aim: We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p < 0.0001) and time to next treatment (HR: 0.36 [0.27-0.49]; p < 0.0001) versus the RWPC cohort. Conclusion: Teclistamab offered clinical benefit over RWPC in triple-class exposed relapsed/refractory multiple myeloma.
Keywords: treatment outcome; antineoplastic agents; antineoplastic agent; multiple myeloma; antineoplastic combined chemotherapy protocols; dexamethasone; physicians; physician; comparative effectiveness; bispecific antibody; humans; human; b-cell maturation antigen; indirect treatment comparison; majestec-1
Journal Title: Journal of Comparative Effectiveness Research
Volume: 12
Issue: 6
ISSN: 2042-6305
Publisher: Future Medicine  
Date Published: 2023-06-01
Start Page: e220186
Language: English
DOI: 10.57264/cer-2022-0186
PUBMED: 37114426
PROVIDER: scopus
PMCID: PMC10402759
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Saad Zafar Usmani
    300 Usmani